Nobel Lecture: Gregg L. Semenza, Nobel Prize in Physiology or Medicine 2019

Transcript

[Applause] Nobel laureates excellencies ladies and gentlemen it's a great pleasure and indeed a privilege to welcome all of you to Korea's constituted all-america we're here for the 2019 Nobel lectures in Physiology or medicine my name is Ollie Olsen and I'm the president of Karolinska Institutet during the Nobel week and particularly I should say ... Read More

Summary

In this video, the Nobel laureates in Physiology or Medicine for 2019, William Kaelin Jr., Sir Peter Ratcliffe, and Gregg Semenza, give lectures on their groundbreaking discoveries on how cells sense and adapt to oxygen availability. They discuss the role of the hypoxia-inducible factors (HIFs) in regulating oxygen homeostasis and its implications in various diseases such as anemia, cardiovascular disease, and cancer. They also explore the potential of targeting the HIF pathway for therapeutic interventions.

Questions & Answers

Q: How do cells sense and adapt to changes in oxygen availability?

Cells sense and adapt to changes in oxygen availability through a master regulator called hypoxia-inducible factor (HIF). HIF is composed of two subunits, HIF-1α and HIF-1β, and under hypoxic conditions, HIF-1α accumulates within cells and forms a complex with HIF-1β. This complex then binds to specific DNA sequences known as hypoxia response elements (HREs) in the genes involved in oxygen homeostasis, leading to the activation of gene expression. In this way, cells can respond to changes in oxygen levels by altering their metabolism, immune responses, and other functional properties.

Q: How do HIFs regulate red blood cell production?

HIFs play a crucial role in the regulation of red blood cell production. The production of erythropoietin (EPO), a hormone responsible for stimulating red blood cell production, is controlled by HIFs. Under normal oxygen conditions, HIF-1α is hydroxylated and targeted for degradation by the von Hippel-Lindau (VHL) protein. However, under hypoxic conditions, HIF-1α is stabilized and can bind to HREs in the EPO gene, resulting in increased EPO production. This, in turn, stimulates the production of red blood cells, ensuring an adequate oxygen supply to the body.

Q: What happens when HIFs are dysfunctional?

Dysfunction in the HIF pathway can have detrimental effects on human health. For example, mutations in HIF or its regulatory proteins can lead to conditions such as congenital polycythemia, where there is excessive red blood cell production, or critical limb ischemia, where there is inadequate blood flow to the limbs. Additionally, dysregulated HIF signaling has been implicated in cancer progression and resistance to therapy. High levels of HIF in cancer cells promote tumor growth, invasion, metastasis, and the evasion of immune responses. Understanding the role of HIFs in these diseases has opened up new possibilities for targeted therapies.

Q: Can HIF inhibitors be used in cancer therapy?

Yes, HIF inhibitors have shown promise as potential cancer therapies. By blocking HIF activity, these inhibitors can disrupt the ability of cancer cells to adapt to hypoxic conditions and evade immune responses. Studies in animal models, such as mice with prostate or breast cancer, have demonstrated that HIF inhibitors can inhibit tumor growth, prevent metastasis, and enhance the efficacy of chemotherapy. Moreover, the high expression of HIF in human cancer tissues has been associated with poor patient outcomes, making HIF a potential target for personalized cancer treatments. However, further research and development are needed to optimize HIF inhibitors for clinical use.

Q: Are there any clinical applications of HIF research?

Research on HIFs has not only provided valuable insights into the fundamental understanding of oxygen homeostasis but also has significant clinical implications. The HIF pathway is involved in various disease processes, including anemia, cardiovascular diseases, and cancer. In anemia, where there is a deficiency in red blood cells or EPO production, HIF activators or stabilizers could be used to stimulate red blood cell production. In cardiovascular diseases, HIF manipulation could potentially enhance blood vessel growth and improve tissue oxygenation. Furthermore, targeting HIFs in cancer therapy holds promise for inhibiting tumor growth, metastasis, and drug resistance. Efforts are underway to develop drugs and therapies that specifically target the HIF pathway to address these clinical challenges.

Q: What is the importance of aging in HIF regulation and disease progression?

Aging has been shown to impair the HIF response and contribute to disease progression. As we age, the ability of our cells and tissues to adapt to changes in oxygen availability is diminished. For example, in older individuals, the recovery of blood flow after a limb ischemia event is significantly reduced compared to young individuals. This impairment in HIF response correlates with a decrease in the induction of HIF-1α protein and a higher risk of tissue injury and amputation. Understanding the age-related changes in HIF regulation could help develop strategies to enhance HIF activity and improve the outcomes of diseases associated with impaired oxygen homeostasis.

Q: Can HIF inhibition be used as a strategy to enhance sensitivity to chemotherapy in cancer treatment?

Yes, combining HIF inhibition with chemotherapy has shown promising results in preclinical studies. HIFs are known to play a role in promoting the survival and resistance of cancer cells to chemotherapy. By targeting HIFs, it is possible to sensitize cancer cells to chemotherapy and enhance the efficacy of the treatment. In animal models of breast cancer, for example, combining the HIF inhibitor digoxin with the chemotherapeutic drug gemcitabine was able to completely eradicate the tumor. These findings suggest that HIF inhibition could be a valuable strategy to overcome drug resistance and improve patient outcomes in cancer treatment.

Q: Can HIF inhibitors be used to enhance immune responses against cancer cells?

Yes, targeting HIFs can help enhance immune responses against cancer cells. HIFs play a role in regulating the expression of proteins involved in immune evasion by cancer cells. For instance, HIFs can upregulate the expression of proteins like PD-L1, which interacts with PD-1 receptors on immune cells and inhibits their function. By inhibiting HIFs, it is possible to reduce the expression of these immunosuppressive proteins and restore immune responses against cancer cells. This approach can be combined with immune checkpoint inhibitors or other immunotherapies to enhance the effectiveness of cancer immunotherapy.

Q: Are there any challenges in developing HIF inhibitors for clinical use?

Developing HIF inhibitors for clinical use presents several challenges. One major challenge is specificity, as HIFs are involved in important physiological processes beyond disease-related pathways. It is crucial to develop inhibitors that selectively target cancer-specific HIF pathways to minimize off-target effects on normal tissue. Additionally, optimizing the drug properties to ensure sufficient bioavailability, stability, and efficacy is challenging. Another consideration is the potential side effects of HIF inhibition, as complete inhibition of HIF activity could have unintended consequences on normal physiological processes. Ongoing research is focused on overcoming these challenges and developing safe and effective HIF inhibitors for targeted therapies.

Q: What are the potential future directions in HIF research and therapy?

Future research in HIF biology and therapy is likely to focus on several areas. First, refining the understanding of the structural and functional aspects of HIFs and their interaction with regulatory proteins will provide insights into potential therapeutic targets. Second, identifying and validating new small molecule inhibitors or gene-based approaches that specifically target disease-related HIF pathways will be a priority. Third, optimizing drug delivery strategies to ensure efficient targeting of HIF activity within tumors or specific tissues will be key. Finally, conducting large-scale clinical trials to evaluate the safety and efficacy of HIF inhibitors in different disease contexts will be necessary to bridge the gap between preclinical findings and clinical applications.

Takeaways

The lectures by the Nobel laureates highlight the groundbreaking discoveries on how cells sense and adapt to oxygen availability through the hypoxia-inducible factors (HIFs). The HIF pathway, consisting of HIF-1α and HIF-1β subunits, plays a vital role in regulating oxygen homeostasis and has profound implications in various diseases such as cancer, anemia, and cardiovascular diseases. Understanding the mechanisms behind HIF regulation and dysfunction has paved the way for potential therapeutic interventions targeting the HIF pathway. The development of HIF inhibitors holds promise for improving patient outcomes and enhancing the effectiveness of existing therapies. However, challenges remain in terms of specificity, drug optimization, and minimizing side effects. Further research and clinical trials are needed to fully harness the potential of HIF inhibitors and realize their clinical applications.